Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
2.995
-0.075 (-2.43%)
Mar 9, 2026, 1:53 PM EDT - Market open
Evotec SE Revenue
Evotec SE had revenue of 163.89M EUR in the quarter ending September 30, 2025, a decrease of -11.36%. This brings the company's revenue in the last twelve months to 756.33M, down -2.67% year-over-year. In the year 2024, Evotec SE had annual revenue of 796.97M with 1.99% growth.
Revenue (ttm)
756.33M EUR
Revenue Growth
-2.67%
P/S Ratio
1.25
Revenue / Employee
157,963 EUR
Employees
4,788
Market Cap
1.11B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.25B |
| ANI Pharmaceuticals | 883.37M |
| Tilray Brands | 837.32M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 573.35M |
| Harrow | 272.30M |
EVO News
- 2 months ago - Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Accesswire
- 2 months ago - Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Accesswire
- 3 months ago - Evotec: How Low A Company May Go While Still Being Attractive - Seeking Alpha
- 3 months ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 3 months ago - Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome - Accesswire
- 4 months ago - Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Accesswire
- 4 months ago - Evotec SE (EVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire